The past 20 months has seen an explosion of vaccine development, with COVID vaccine testing and rollout happening at an unprecedented pace in the face of a global pandemic. There have been absolute triumphs – the fact we have multiple safe, effective vaccines is remarkable – but there have also been challenges.
We’ve seen storage and delivery issues, vaccine hesitancy, breakthrough infections and the beginnings of waning immunity.
Vaccine innovators around the world have these challenges in their sights. They are already working on the next generation of COVID vaccines.
Tweaking Current Vaccines
After hundreds of millions of doses, we have a good handle on how current vaccines are performing and where they can be improved. As more data is gathered, a modified dose, time between doses, and/or using different vaccines together in mix-and-match strategies may become the preferred approach.
We could also improve vaccines that aren’t performing at their best.
One way to improve this could be to add an adjuvant – something that fires up the immune system. One such vaccine, called Valneva, has early results that suggest including an adjuvant improves immunity.
Making Vaccination Easier
As we have seen, vaccinating large numbers of people is not easy. Innovations to make this easier will be welcome.
Needle-free approaches would be ideal. One approach, known as a nanopatch vaccine, coats the vaccine onto tiny spikes on a small patch.
The patch is applied to the skin and the spikes deliver the vaccine to a dense barrier of immune cells sitting just under the top layers of our skin. A nanopatch COVID vaccine developed by Vaxxas and researchers in Queensland has been shown to trigger strong immune responses in animal models, with trials underway in humans.
Another approach, known as an intranasal vaccine, sprays a vaccine up the nose. This would be easier to deliver and it could also build immunity in the right location in our body.
The coronavirus infects us through the lining of the nose, mouth, throat and lungs – a type of sticky tissue that lines body cavities and some organs called mucosa.
Currently, COVID vaccines are delivered into our arm muscle and build antibody levels in our blood and tissue, with some antibody spilling out into the mucosa. Delivering the vaccine directly to the mucosa might be a better approach for preventing COVID infection. This is being trialled with a number of vaccines, including the AstraZeneca vaccine.
If yearly COVID boosters are recommended for some or even all of the population, it would be easier to deliver them together with the yearly flu vaccine. These “multipathogen” vaccines are being tested with current flu vaccine or even new types of flu vaccine.
More Durable Immunity
With two doses of the current vaccines, immunity is seen to decline and poor responses are seen in certain groups such as the severely immune-compromised and older people. COVID vaccines that can induce more durable immunity, more consistently across vulnerable populations would be a major innovation.
This could require completely new vaccines. Protein subunit vaccines – which use purified protein from the surface of the virus as a target – are still working their way through approvals around the world.
One example is the Novavax vaccine, but there are a large number of other protein subunit vaccines also development that often use new adjuvants – again, the vaccine ingredient that fires up your immune system. These new adjuvants could support more durable immunity but this remains to be tested.
Protection Against Future Variants
We can also update the current vaccines by changing their target. All current COVID vaccines use a target from the original strain of the coronavirus to train the immune system.
This is okay for vaccinating against the Delta strain, as this new virus still looks pretty similar to the original virus to your immune system. But new viruses could emerge that the immune system struggles to recognise.
We could simply use a new target from a new virus. Some vaccines have been updated to target the Beta strain, which is relatively hard for our immune system to recognise. Trials are being run with these Beta-targeted vaccines as a dry run, to make sure that we can update vaccines if we need to.
A more ambitious approach would be to focus the immune response on a target/s common to all coronaviruses. This “pan-coronavirus” vaccine would hopefully provide protection from all or most coronaviruses. Again, early data from animal models are promising.
Working Out if Vaccines Are Working
An important innovation for COVID vaccines would be an immune correlate.
An immune correlate is something that can be measured in an immune response to indicate if someone will be protected against infection or not. For rubella and hepatitis B virus, we measure the amount of antibody targeting these viruses in our blood. If antibody is absent or too low, a booster dose of the vaccine is recommended.
An immune correlate for COVID could similarly allow us to identify people that need a booster.
Some researchers, including Australian teams, are sorting through data from around the world to see if there is something we can measure in our immune response to use as a correlate for COVID.
Research around the world is driving us towards the next generation of COVID vaccines. Innovations for COVID vaccines will lead to better vaccines for other infections too – those that currently afflict humanity and those that are yet to emerge.
ABOUT THE AUTHOR
Dr. Kylie Quinn is an RMIT University Vice-Chancellor’s Research Fellow and leads the new Ageing and Immunotherapies Group. Her group is developing ways to improve immune responses in older individuals during infection, vaccination, and new cell-based therapies such as chimeric antigen receptor T cell therapy (CTT). CTT can achieve remarkable remission rates in haematological cancers. Unfortunately, this efficacy can be reduced in older patients, as their immune cells are more difficult to activate. Her work aims to identify what limits this activation of immune cells and to remove that barrier for older patients. Previously, she trained at the Vaccine Research Center (VRC), NIAID/NIH, USA with Dr Robert Seder. At the VRC, she defined the mechanism of action for several novel vaccines and provided key pre-clinical data for Ebola vaccine selection by the World Health Organisation in 2014. She has received several awards for her work, including the John and Eileen Haddon Award for Geriatric Research from the Rebecca L Cooper Foundation and the Maxwell Eagle Endowment Award for Cancer Research at RMIT. More broadly, Kylie has a long-standing interest in issues of equity and inclusion in science and is the current Australia and New Zealand Society of Immunology Women’s Initiative Coordinator.
This article is courtesy of The Conversation.